DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
DarioHealth Corp.NASDAQ: DRIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $8.25M (cash outflow) fell 10.6% year over year, ahead of the -27.8% change in trailing-twelve-month net income. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at -12.5% a year.
Context
- Net income amounted to 186.6% of revenue in FY2025, up 28.5 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$206.54M (+395.1%) for the fiscal year ending Dec 2026, a step up from the -2.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.25M-8.7% QoQ
- Last fiscal yearDec 2025
- -$41.71M-2.4% YoY
- LTMMar 2026
- -$32.35M-27.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.6% | -12.6% | -2.0 pp |
| 1 year | -2.4% | +395.1% | +397.5 pp |
| 3-year CAGR | -12.5% | +31.1% | +43.6 pp |
| 5-year CAGR | +6.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (41.71M) USD
- Year-over-year change
- +2.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.71M) | +2.4% |
| FY2024 | 2024-12-31 | (42.75M) | +28.1% |
| FY2023 | 2023-12-31 | (59.43M) | +4.4% |
| FY2022 | 2022-12-31 | (62.19M) | +19.0% |
| FY2021 | 2021-12-31 | (76.76M) | — |
Net Income vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 net income of $32.35M is the 9th largest of the 11 companies compared; the peer median is $123.51M.
- Its year-over-year change of -27.8% is the 8th highest of 11, against a peer median of +27.4%.
- Net income amounts to 152.6% of revenue for DRIO, versus a peer median of 56.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
| LTM Mar 2026 | $178.05M | +24.5% | +67.1% | 21.6% | |
| LTM Mar 2026 | $128.58M | -80.5% | +20.2% | 80.3% | |
| LTM Mar 2026 | $118.44M | +10.2% | +3.2% | 6450.8% | |
| LTM Mar 2026 | $74.56M | +78.1% | — | 23.3% | |
| LTM Mar 2026 | $74.4M | -80.7% | — | 10.4% | |
| LTM Mar 2026 | $32.35M | -27.8% | -12.5% | 152.6% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.4M | +169.9% | -13.8% | 65.6% |
| LTM Mar 2026 | $4.33M | -86.4% | +75.7% | 0.5% | |
| Peer median (excluding DRIO) | $123.51M | +27.4% | +30.9% | 56.9% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M |
| Change in Working Capital | (2.57M) | (10.9M) | 4.07M | (2.47M) | 2.21M |
| Accounts Receivables | (367K) | (5.11M) | 2.84M | 1.6M | 2.64M |
| Inventory | (2.23M) | (1.73M) | 2.89M | 308K | 437K |
| Accounts Payables | 1.08M | (2.79M) | (1.19M) | (496K) | (122K) |
| Other Working Capital | (1.06M) | (1.28M) | (464K) | (3.88M) | (752K) |
| Other Non-Cash Items | (503K) | 3.56M | 288K | (16.57M) | 1.37M |
| Operating Cash Flow | (50.41M) | (47.85M) | (30.38M) | (38.56M) | (25.94M) |
| Capital Expenditures | (261K) | (573K) | (584K) | (138K) | (142K) |
| Acquisitions (Net) | (7.47M) | 0 | 0 | (8.8M) | 0 |
| Purchases of Investments | 0 | 0 | (5M) | 0 | (4.2M) |
| Sales of Investments | 0 | 0 | 5.03M | 0 | 0 |
| Other Investing Activities | (400K) | (131K) | 0 | 0 | 0 |
| Investing Cash Flow | (8.13M) | (573K) | (547K) | (8.93M) | (4.34M) |
| Debt Repayment | 0 | 23.79M | 1.77M | 0 | 185K |
| Common Stock Issued | 64.88M | 38.29M | 1.61M | 0 | 24.13M |
| Common Stock Repurchased | 0 | (134K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 889K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M |
| Effect of Forex Changes | 0 | 0 | 0 | (68K) | 9K |
| Net Change in Cash | 7.22M | 13.52M | (12.67M) | (9.03M) | (5.96M) |
| Free Cash Flow | (50.67M) | (48.42M) | (30.96M) | (38.7M) | (26.08M) |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.